Latest News

Complimentary Webinar: Optimizing the Use of Clinical Trial Disclosure Systems

MMS is collaborating with the DIA for an upcoming complimentary webinar, “Optimizing the Use of Clinical Trial Disclosure Systems to Meet Complex and Evolving Global Regulatory Requirements.”

Learning Objectives

  • Determine key drivers for the use of technology to manage clinical trial disclosures processes
  • Implement efficiencies and consistencies gained from enabling reuse of protocol and results summary content across regions
  • Understand the importance of integrating drug and submission-level metrics into disclosures systems
  • Identify system features and functionality that are key to achieving global compliance
  • Recognize the importance of automated workflow management to manage the disclosures life cycle

Presenters

  • Kasim McLain, Manager, Disclosure Services, MMS
  • Peggy Zorn, MS, MBA, Associate Director, Regulatory Affairs, Submissions and Transparency, MMS
  • Gitta Irmer, MS, Associate Director, Data Quality and Standards, Eisai
  • Zach Weingarden, MS, Product Solutions Manager, TrialAssure

View the webinar by clicking here!

Suggested For You

news

September 26th, 2017

Pfizer Selects MMS as Preferred Provider for Plain Language Summary Writing Support

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan

perspectives

May 29th, 2024

Confined Deferrals in Clinical Trial Applications: Anticipating the Revised EU CTR Transparency Rules

webinar

January 18th, 2024

EU Clinical Trials Regulation: The Clinical Trial Transparency Revolution

webinar

January 17th, 2024

EU CTR Compliance and Success: Navigating Updates and Preparing Submissions for the EU CTIS Portal

perspectives

November 7th, 2023

Plain Language Protocol Synopsis – Meeting the EU Regulation

perspectives

October 13th, 2023

EMA Revised Transparency Rules Eliminate the Deferral Mechanism for Clinical Trial Data Publication

perspectives

October 3rd, 2023

Plain Language Summary of Publications: A Key Step To Build Transparency With The Patient Community

perspectives

September 6th, 2023

Relaunch of EMA Policy 0070 in September 2023: The European Medicines Agency’s Revived Commitment to Transparency

perspectives

June 28th, 2023

EMA Policy 0070: Much Awaited Revamp for Clinical Trial Transparency

perspectives

November 30th, 2022

A Step-by-Step Approach to Determining Company Confidential Information (CCI) in Redaction Proposal Packages

perspectives

September 15th, 2022

How does the European Union Clinical Trial Information System (EU-CTIS) Affect Clinical Trial Transparency?